NEW YORK, Sept. 9, 2013 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) will host Hope on the Horizon: New Drugs for Alzheimer's Disease. The luncheon and symposium will honor Liz and Randal Sandler with the Charles Evans Award for their longtime commitment to the Alzheimer's community.
The event, hosted by Paula Zahn, Norah O'Donnell, and chaired by Leonard A. Lauder, ADDF co-founder and chairman, will announce promising developments in treatments to detect, prevent and cure Alzheimer's and related dementias. The luncheon will also raise critical dollars to support Alzheimer's drug research – 100% of donations will go to research and related programs. Alzheimer's is a progressive, fatal disease of the brain that affects an estimated 5.2 million people in the U.S., but there are no treatments currently available to treat or even slow the disease.
WHEN: Tuesday, September 17, 2013
TIME: 10:30 AM – 2:00 PM EDT
WHERE: The Pierre, 2 East 61st Street, New York City
350 of NYC's business, social and civic leaders are expected to attend. Additional event details:
- Morning symposium hosted by Norah O'Donnell, co-anchor of CBS This Morning, will include a presentation by Howard Fillit, MD, executive director and chief science officer of the ADDF, titled Alzheimer's Disease: A Progress Report
- Onstage interview by Paula Zahn, award winning journalist and newscaster, and host of On the Case with Paula Zahn, with Jeffrey L. Cummings, MD, ScD, Director, Cleveland Clinic Lou Ruvo Center for Brain Heath; Camille and Larry Ruvo Chair for Brain Health; Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
- Silent auction and launch of designer Gomez-Gracia's exclusive Horizon Tank, benefiting the ADDF
About the ADDF
Founded in 1998 by Leonard A. and Ronald S. Lauder, the mission of the Alzheimer's Drug Discovery Foundation (ADDF) is to rapidly accelerate the discovery of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging. The ADDF has invested nearly $60 million to fund 400 Alzheimer's drug discovery programs in academic centers and biotechnology companies in 18 countries. For more information, please visit www.AlzDiscovery.org.
SOURCE Alzheimer's Drug Discovery Foundation